Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III melanoma with BRAF V600 mutations resulted in relapse-free survival of 52%, as compared with 36% with placebo.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2020-09, Vol.383 (12), p.1139-1148 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1148 |
|---|---|
| container_issue | 12 |
| container_start_page | 1139 |
| container_title | The New England journal of medicine |
| container_volume | 383 |
| creator | Dummer, Reinhard Hauschild, Axel Santinami, Mario Atkinson, Victoria Mandalà, Mario Kirkwood, John M Chiarion Sileni, Vanna Larkin, James Nyakas, Marta Dutriaux, Caroline Haydon, Andrew Robert, Caroline Mortier, Laurent Schachter, Jacob Lesimple, Thierry Plummer, Ruth Dasgupta, Kohinoor Gasal, Eduard Tan, Monique Long, Georgina V Schadendorf, Dirk |
| description | At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III melanoma with
BRAF
V600 mutations resulted in relapse-free survival of 52%, as compared with 36% with placebo. |
| doi_str_mv | 10.1056/NEJMoa2005493 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2443616836</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2443616836</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-ab44361311fbd5257d018440b807b17ce1bb09306cb8565a46e263d9eb1ea813</originalsourceid><addsrcrecordid>eNp1kL1PwzAUxC0EEqUwsltCjAG_-CPJWJUWglo60IXJek4clCgfxU4q9b8npSwMvOX0pJ9Od0fILbAHYFI9vi1e1x2GjEmR8DMyAcl5IART52TCWBgHIkr4JbnyvmLjgUgmZLMs9zb4sOjorMX64EtPu4LO8mrYY9vTJzQOC9uWhu7qwdOtw8b25fEvW_re46elaZrSta2x7Rq8JhcF1t7e_OqUbJeL7fwlWG2e0_lsFWQCoA_QCMEVcIDC5DKUUc4gHqOamEUGosyCMSzhTGUmlkqiUDZUPE-sAYsx8Cm5O9nuXPc1WN_rqhvcWMDr8MdZxVyNVHCiMtd572yhd65s0B00MH2cTP-ZbOTvT3zTeN3aqvmH-waDo2gR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2443616836</pqid></control><display><type>article</type><title>Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Dummer, Reinhard ; Hauschild, Axel ; Santinami, Mario ; Atkinson, Victoria ; Mandalà, Mario ; Kirkwood, John M ; Chiarion Sileni, Vanna ; Larkin, James ; Nyakas, Marta ; Dutriaux, Caroline ; Haydon, Andrew ; Robert, Caroline ; Mortier, Laurent ; Schachter, Jacob ; Lesimple, Thierry ; Plummer, Ruth ; Dasgupta, Kohinoor ; Gasal, Eduard ; Tan, Monique ; Long, Georgina V ; Schadendorf, Dirk</creator><creatorcontrib>Dummer, Reinhard ; Hauschild, Axel ; Santinami, Mario ; Atkinson, Victoria ; Mandalà, Mario ; Kirkwood, John M ; Chiarion Sileni, Vanna ; Larkin, James ; Nyakas, Marta ; Dutriaux, Caroline ; Haydon, Andrew ; Robert, Caroline ; Mortier, Laurent ; Schachter, Jacob ; Lesimple, Thierry ; Plummer, Ruth ; Dasgupta, Kohinoor ; Gasal, Eduard ; Tan, Monique ; Long, Georgina V ; Schadendorf, Dirk</creatorcontrib><description>At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III melanoma with
BRAF
V600 mutations resulted in relapse-free survival of 52%, as compared with 36% with placebo.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2005493</identifier><language>eng</language><publisher>Boston: Massachusetts Medical Society</publisher><subject>Adjuvants ; Inhibitor drugs ; Melanoma ; Metastases ; Metastasis ; Mutation ; Survival ; Survival analysis ; Targeted cancer therapy</subject><ispartof>The New England journal of medicine, 2020-09, Vol.383 (12), p.1139-1148</ispartof><rights>Copyright © 2020 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-ab44361311fbd5257d018440b807b17ce1bb09306cb8565a46e263d9eb1ea813</citedby><cites>FETCH-LOGICAL-c411t-ab44361311fbd5257d018440b807b17ce1bb09306cb8565a46e263d9eb1ea813</cites><orcidid>0000-0003-3524-7858</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2005493$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa2005493$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids></links><search><creatorcontrib>Dummer, Reinhard</creatorcontrib><creatorcontrib>Hauschild, Axel</creatorcontrib><creatorcontrib>Santinami, Mario</creatorcontrib><creatorcontrib>Atkinson, Victoria</creatorcontrib><creatorcontrib>Mandalà, Mario</creatorcontrib><creatorcontrib>Kirkwood, John M</creatorcontrib><creatorcontrib>Chiarion Sileni, Vanna</creatorcontrib><creatorcontrib>Larkin, James</creatorcontrib><creatorcontrib>Nyakas, Marta</creatorcontrib><creatorcontrib>Dutriaux, Caroline</creatorcontrib><creatorcontrib>Haydon, Andrew</creatorcontrib><creatorcontrib>Robert, Caroline</creatorcontrib><creatorcontrib>Mortier, Laurent</creatorcontrib><creatorcontrib>Schachter, Jacob</creatorcontrib><creatorcontrib>Lesimple, Thierry</creatorcontrib><creatorcontrib>Plummer, Ruth</creatorcontrib><creatorcontrib>Dasgupta, Kohinoor</creatorcontrib><creatorcontrib>Gasal, Eduard</creatorcontrib><creatorcontrib>Tan, Monique</creatorcontrib><creatorcontrib>Long, Georgina V</creatorcontrib><creatorcontrib>Schadendorf, Dirk</creatorcontrib><title>Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma</title><title>The New England journal of medicine</title><description>At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III melanoma with
BRAF
V600 mutations resulted in relapse-free survival of 52%, as compared with 36% with placebo.</description><subject>Adjuvants</subject><subject>Inhibitor drugs</subject><subject>Melanoma</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Targeted cancer therapy</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kL1PwzAUxC0EEqUwsltCjAG_-CPJWJUWglo60IXJek4clCgfxU4q9b8npSwMvOX0pJ9Od0fILbAHYFI9vi1e1x2GjEmR8DMyAcl5IART52TCWBgHIkr4JbnyvmLjgUgmZLMs9zb4sOjorMX64EtPu4LO8mrYY9vTJzQOC9uWhu7qwdOtw8b25fEvW_re46elaZrSta2x7Rq8JhcF1t7e_OqUbJeL7fwlWG2e0_lsFWQCoA_QCMEVcIDC5DKUUc4gHqOamEUGosyCMSzhTGUmlkqiUDZUPE-sAYsx8Cm5O9nuXPc1WN_rqhvcWMDr8MdZxVyNVHCiMtd572yhd65s0B00MH2cTP-ZbOTvT3zTeN3aqvmH-waDo2gR</recordid><startdate>20200917</startdate><enddate>20200917</enddate><creator>Dummer, Reinhard</creator><creator>Hauschild, Axel</creator><creator>Santinami, Mario</creator><creator>Atkinson, Victoria</creator><creator>Mandalà, Mario</creator><creator>Kirkwood, John M</creator><creator>Chiarion Sileni, Vanna</creator><creator>Larkin, James</creator><creator>Nyakas, Marta</creator><creator>Dutriaux, Caroline</creator><creator>Haydon, Andrew</creator><creator>Robert, Caroline</creator><creator>Mortier, Laurent</creator><creator>Schachter, Jacob</creator><creator>Lesimple, Thierry</creator><creator>Plummer, Ruth</creator><creator>Dasgupta, Kohinoor</creator><creator>Gasal, Eduard</creator><creator>Tan, Monique</creator><creator>Long, Georgina V</creator><creator>Schadendorf, Dirk</creator><general>Massachusetts Medical Society</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><orcidid>https://orcid.org/0000-0003-3524-7858</orcidid></search><sort><creationdate>20200917</creationdate><title>Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma</title><author>Dummer, Reinhard ; Hauschild, Axel ; Santinami, Mario ; Atkinson, Victoria ; Mandalà, Mario ; Kirkwood, John M ; Chiarion Sileni, Vanna ; Larkin, James ; Nyakas, Marta ; Dutriaux, Caroline ; Haydon, Andrew ; Robert, Caroline ; Mortier, Laurent ; Schachter, Jacob ; Lesimple, Thierry ; Plummer, Ruth ; Dasgupta, Kohinoor ; Gasal, Eduard ; Tan, Monique ; Long, Georgina V ; Schadendorf, Dirk</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-ab44361311fbd5257d018440b807b17ce1bb09306cb8565a46e263d9eb1ea813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adjuvants</topic><topic>Inhibitor drugs</topic><topic>Melanoma</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dummer, Reinhard</creatorcontrib><creatorcontrib>Hauschild, Axel</creatorcontrib><creatorcontrib>Santinami, Mario</creatorcontrib><creatorcontrib>Atkinson, Victoria</creatorcontrib><creatorcontrib>Mandalà, Mario</creatorcontrib><creatorcontrib>Kirkwood, John M</creatorcontrib><creatorcontrib>Chiarion Sileni, Vanna</creatorcontrib><creatorcontrib>Larkin, James</creatorcontrib><creatorcontrib>Nyakas, Marta</creatorcontrib><creatorcontrib>Dutriaux, Caroline</creatorcontrib><creatorcontrib>Haydon, Andrew</creatorcontrib><creatorcontrib>Robert, Caroline</creatorcontrib><creatorcontrib>Mortier, Laurent</creatorcontrib><creatorcontrib>Schachter, Jacob</creatorcontrib><creatorcontrib>Lesimple, Thierry</creatorcontrib><creatorcontrib>Plummer, Ruth</creatorcontrib><creatorcontrib>Dasgupta, Kohinoor</creatorcontrib><creatorcontrib>Gasal, Eduard</creatorcontrib><creatorcontrib>Tan, Monique</creatorcontrib><creatorcontrib>Long, Georgina V</creatorcontrib><creatorcontrib>Schadendorf, Dirk</creatorcontrib><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dummer, Reinhard</au><au>Hauschild, Axel</au><au>Santinami, Mario</au><au>Atkinson, Victoria</au><au>Mandalà, Mario</au><au>Kirkwood, John M</au><au>Chiarion Sileni, Vanna</au><au>Larkin, James</au><au>Nyakas, Marta</au><au>Dutriaux, Caroline</au><au>Haydon, Andrew</au><au>Robert, Caroline</au><au>Mortier, Laurent</au><au>Schachter, Jacob</au><au>Lesimple, Thierry</au><au>Plummer, Ruth</au><au>Dasgupta, Kohinoor</au><au>Gasal, Eduard</au><au>Tan, Monique</au><au>Long, Georgina V</au><au>Schadendorf, Dirk</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma</atitle><jtitle>The New England journal of medicine</jtitle><date>2020-09-17</date><risdate>2020</risdate><volume>383</volume><issue>12</issue><spage>1139</spage><epage>1148</epage><pages>1139-1148</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III melanoma with
BRAF
V600 mutations resulted in relapse-free survival of 52%, as compared with 36% with placebo.</abstract><cop>Boston</cop><pub>Massachusetts Medical Society</pub><doi>10.1056/NEJMoa2005493</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-3524-7858</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2020-09, Vol.383 (12), p.1139-1148 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_2443616836 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adjuvants Inhibitor drugs Melanoma Metastases Metastasis Mutation Survival Survival analysis Targeted cancer therapy |
| title | Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T01%3A47%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Five-Year%20Analysis%20of%20Adjuvant%20Dabrafenib%20plus%20Trametinib%20in%20Stage%20III%20Melanoma&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Dummer,%20Reinhard&rft.date=2020-09-17&rft.volume=383&rft.issue=12&rft.spage=1139&rft.epage=1148&rft.pages=1139-1148&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2005493&rft_dat=%3Cproquest_cross%3E2443616836%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2443616836&rft_id=info:pmid/&rfr_iscdi=true |